Patients having prophylactic surgery for family history or known genetic mutations: Why save the uterus?

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 780-781

  Geisler, John P ^a  

^a Division of Gynecologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; CASE REPORT; DNA SEQUENCE; ENDOMETRIUM CANCER; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; LETTER; MORBIDITY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROPHYLAXIS; UTERINE PAPILLARY SEROUS CARCINOMA; UTERUS CANCER; UTERUS SURGERY;

ADULT; AGED, 80 AND OVER; BREAST NEOPLASMS; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; UTERINE NEOPLASMS;

EID: 33846913234     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.015     Document Type: Letter

References (9)

1. Frank T.S., and Critchfield G.C. Inherited risk of women's cancers: What's changed for the practicing physician?. Clin. Obstet. Gynecol. 45 (2002) 671-683
2. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol. Oncol. 79 (2000) 477-481
3. Levine D.A., Lin O., Barakat R.R., Robson M.E., McDermott D., Cohen L., et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol. Oncol. 80 (2001) 395-398
4. Hornreich G., Beller U., Lavie O., Renbaum P., Cohen Y., and Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol. Oncol. 75 (1999) 300-304
5. Geisler J.P., Sorosky J.I., Duong H.L., Buekers T.E., Geisler M.J., Sood A.K., et al. Papillary serous carcinoma of the uterus: Increased risk of subsequent or concurrent development of breast carcinoma. Gynecol. Oncol. 83 (2001) 501-503
6. Slomovitz B.M., Burke T.W., Eifel P.J., Ramondetta L.M., Silva E.G., Jhingran A., et al. Uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. Gynecol. Oncol. 91 (2003) 463-469
7. Schubert E.L., Lee M.K., Mefford H.C., Argonza R.H., Morrow J.E., Hull J., et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am. J. Hum. Genet. 60 (1997) 1031-1040
8. Geisler J.P., Rathe J.A., Hatterman-Zogg M.A., Lallas T.A., Kirby P., and Buller R.E. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Human Mutat. 18 (2001) 337-344
9. Geisler J.P., Geisler H.E., Melton M.E., and Wiemann M.C. What staging surgery should be performed on patients with uterine papillary serous carcinoma?. Gynecol. Oncol. 74 (1999) 465-467